Life quality assessment of breast cancer patients receiving adjuvant therapy using incomplete data
β Scribed by Petra Busch; Peter Schwendener; Robert E. Leu; Brigitte Von Dach; Monica Castiglione
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 588 KB
- Volume
- 3
- Category
- Article
- ISSN
- 1057-9230
No coin nor oath required. For personal study only.
β¦ Synopsis
Previous research on the effects of adjuvant treatment for women with operable breast cancer focused exclusively on disease-free and overall survival. In this study we evaluate life quality of premenopausal node-positive breast cancer patients receiving adjuvant chemotherapy for at least three months. For the first time, a modified latent variable model is used to assess treatment outcome in a prospective clinical trial. This poses a number of econometric problems which did not occur in the preceding studies. One of them is how to deal with patients whose records are incomplete. The data are provided by the International Breast Cancer Study Group (study VI).
The results indicate that the lowest dose treatment improves life quality faster than the remaining three alternatives. At the end of the 24 months observation period no significant differences between the four treatment options remain. Although the lowest dose treatment is also the least costly no definite conclusion regarding costeffectiveness can be drawn at this stage since survival data is not yet available.
π SIMILAR VOLUMES
We have previously developed a quantitative PCR (QPCR) technique for the detection of cytokeratin 19 (CK19) transcripts in blood and bone marrow and compared this to immunocytochemistry (ICC). Together, both have shown promise for monitoring therapeutic efficacy in patients with metastatic breast ca
This paper describes compliance with the completion of a quality of life questionnaire in the Breast Cancer Prevention Trial, a large multi-centre randomized trial that is studying the efficacy of Tamoxifen in preventing breast cancer. In the first 4875 women enrolled in the control arm of the study
## Background: Hemoglobin increases have been associated with quality of life (qol) improvements in anemic cancer patients treated with epoetin alfa, but intervention generally has been reserved for symptomatic anemia or hemoglobin < 10 g/dl. relationships among hemoglobin, functional status, and p
## Abstract DOI 10.1002/cncr.11430